Table 4.

Validation of methylation by pyrosequencing in an independent batch tissue samples from 20 patients representing each group

GeneSensitivity (95% CI)Specificity (95% CI)AUCt test (P)
Group 1a
 HIF3A90.0 (68.3–98.77)100 (83.1–100)0.9320.0001
 HAAO89.4 (66.8–98.7)100 (83.1–100)0.9470.0001
 RARβ84.2 (60.4–96.6)100 (82.3–100)0.9120.0001
 GSTP194.7 (73.9–99.8)100 (82.3–100)0.9770.0001
Group 2b
 CRIP165.0 (40.7–84.6)65.6 (40.7–84.6)0.7270.0139
 RUNX370.4 (45.7–88.1)75.3 (50.9–91.3)0.7880.0018
 HS3ST265.0 (40.8–84.6)60.0 (36.0–80.9)0.7330.0115
 FLNC70.3 (45.7–88.1)60.4 (36.0–80.8)0.6600.0835
 RASGRF275.7 (50.9–91.3)55.2 (31.5–76.9)0.6820.0515
Group 3c
 PHLDA365.6 (40.7–84.6)65.0 (40.7–84.6)0.730.0129
 RASGRF275.4 (50.9–91.3)60.3 (36.0–80.8)0.7610.0047
 TNFRSF10D60.8 (36.0–80.8)75.6 (50.9–91.3)0.6920.0373
 ZNF13550.0 (27.2–72.8)50.0 (27.2–72.8)0.5550.5518
Group 4d
 BCL11B75.2 (50.9–91.3)60.0 (36.0–80.8)0.7410.0091
 POU3F365.5 (40.7–84.6)70.7 (45.7–88.1)0.7010.0295
 RASGRF270.6 (45.7–88.1)75.4 (50.9–91.3)0.7480.0071

NOTE: Performance of the genes was analyzed by AUC of the genes for the 2 contrast groups. Sensitivity and specificity are reported for the threshold that minimized sensitivity–specificity. The P value indicates the statistical significance. t test p value is obtained by comparing 20 tissues in each group.

Abbreviation: CI, confidence interval.

  • aGenes that are significantly methylated in prostate cancer tissues compared with normal prostate.

  • bHypermethylated genes in tissues of patients with recurrent prostate cancer compared with nonrecurrent tissues.

  • cSignificance of genes methylated in prostate cancer tissues of patients with clinical recurrence compared with patients with only biochemical recurrence.

  • dGenes that are methylated in tissues of patients with systemic recurrence compared with local recurrence.